ATE334119T1 - Geldanamycinderivate zur krebsbehandlung - Google Patents

Geldanamycinderivate zur krebsbehandlung

Info

Publication number: ATE334119T1
Authority: AT; Austria
Prior art keywords: anamycin; money; derivatives; cancer treatment; host
Prior art date: 2001-03-30

Application number

AT02757908T

Other languages

English (en)

Inventor

Kenneth M Snader

B Rao Vishnuvajjala

Melinda G Hollingshead

Edward A Sausville

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2002-03-28

Publication date

2006-08-15

2002-03-28 Application filed by Us Health filed Critical Us Health

2006-08-15 Application granted granted Critical

2006-08-15 Publication of ATE334119T1 publication Critical patent/ATE334119T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
201000011510 cancer Diseases 0.000 title abstract 3
NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical class O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 title 1
230000000694 effects Effects 0.000 abstract 2
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 abstract 2
238000001727 in vivo Methods 0.000 abstract 2
230000001747 exhibiting effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT02757908T 2001-03-30 2002-03-28 Geldanamycinderivate zur krebsbehandlung ATE334119T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US28007801P	2001-03-30	2001-03-30

Publications (1)

Publication Number	Publication Date
ATE334119T1 true ATE334119T1 (de)	2006-08-15

Family

ID=23071560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02757908T ATE334119T1 (de)	2001-03-30	2002-03-28	Geldanamycinderivate zur krebsbehandlung

Country Status (19)

Country	Link
US (1)	US6890917B2 (de)
EP (1)	EP1373215B1 (de)
JP (1)	JP4213472B2 (de)
KR (1)	KR100831133B1 (de)
CN (1)	CN1262542C (de)
AT (1)	ATE334119T1 (de)
AU (1)	AU2002307020B2 (de)
CA (1)	CA2430692C (de)
CY (1)	CY1107484T1 (de)
DE (1)	DE60213386T2 (de)
DK (1)	DK1373215T3 (de)
ES (1)	ES2268068T3 (de)
IL (2)	IL156122A0 (de)
MX (1)	MXPA03007856A (de)
NZ (1)	NZ526133A (de)
PT (1)	PT1373215E (de)
SI (1)	SI21369A (de)
WO (1)	WO2002079167A1 (de)
ZA (1)	ZA200304178B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872715B2 (en) *	2001-08-06	2005-03-29	Kosan Biosciences, Inc.	Benzoquinone ansamycins
US20060148776A1 (en) *	2003-03-13	2006-07-06	Conforma Therapeutics Corporation	Drug formulations having long and medium chain triglycerides
US20050020556A1 (en) *	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020534A1 (en) *	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020557A1 (en) *	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054589A1 (en) *	2003-05-30	2005-03-10	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050054625A1 (en) *	2003-05-30	2005-03-10	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) *	2003-05-30	2010-04-06	Kosan Biosciences Incorporated	Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050026893A1 (en) *	2003-05-30	2005-02-03	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
WO2005009345A2 (en)	2003-06-13	2005-02-03	Kosan Biosciences, Inc.	2-desmethyl ansamycin compounds
CA2545457A1 (en)	2003-11-12	2005-06-23	Kosan Biosciences, Inc.	11-o-methylgeldanamycin compounds
US6855705B1 (en)	2003-11-12	2005-02-15	Kosan Biosciences, Inc.	11-O-methylgeldanamycin compounds
US6887993B1 (en)	2003-11-12	2005-05-03	Kosan Biosciences, Inc.	11-O-methylgeldanamycin compounds
US6875863B1 (en)	2003-11-12	2005-04-05	Kosan Biosciences, Inc.	11-O-methylgeldanamycin compounds
US20060019941A1 (en) *	2003-12-23	2006-01-26	Infinity Pharmaceuticals, Inc.	Analogs of benzoquinone-containing ansamycins and methods of use thereof
BRPI0418147A (pt) *	2003-12-23	2007-04-17	Infinity Pharmaceuticals Inc	análogos de ansamicinas contendo benzoquinona e seus métodos de uso
US20050256097A1 (en) *	2004-05-11	2005-11-17	Kosan Biosciences, Inc.	Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en)	2004-05-20	2007-08-21	Kosan Biosciences Incorporated	Geldanamycin compounds and method of use
US20060067953A1 (en) *	2004-09-29	2006-03-30	Conforma Therapeutics Corporation	Oral pharmaceutical formulations and methods for producing and using same
EP1863769A4 (de) *	2005-03-11	2009-03-18	Univ Colorado	Hsp90-inhibitoren, verfahren zu deren herstellung und deren anwendungen
JP2008539273A (ja) *	2005-04-29	2008-11-13	コーザンバイオサイエンシスインコーポレイテッド	１７−ａａｇ又は１７−ａｇ又はどちらかのプロドラッグをプロテアソーム阻害剤と組み合わせて使用する多発性骨髄腫の治療方法
US20100279994A1 (en) *	2005-06-21	2010-11-04	Inifinity Discovery, Inc.	Ansamycin Formulations and Methods of Use Thereof
WO2007059116A2 (en) *	2005-11-14	2007-05-24	Abraxis Bioscience, Inc.	Geldanamycin derivatives and pharmaceutical compositions thereof
US20090042847A1 (en) *	2005-11-23	2009-02-12	Kosan Biosciences Incorporated	17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) *	2005-11-23	2010-01-19	Bristol-Myers Squibb Company	17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) *	2006-01-18	2007-07-19	Yu Kwok S	Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US20070207992A1 (en) *	2006-02-21	2007-09-06	Board Of Trustees Of Michigan State University	Geldanamycin derivatives and method of use thereof
CN100519536C (zh) *	2006-03-21	2009-07-29	中国医学科学院医药生物技术研究所	一组连有核苷碱基的格尔德霉素衍生物
US20070293451A1 (en) *	2006-05-02	2007-12-20	University Of Pittsburgh	Regulation ao ApoB by Hsp110 proteins and related compositions and methods
KR100796637B1 (ko) *	2006-09-29	2008-01-22	한국생명공학연구원	젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
CN100500668C (zh) *	2006-12-19	2009-06-17	中国人民解放军军事医学科学院毒物药物研究所	格尔德霉素衍生物及其制备方法和制备药物的用途
CN101688227B (zh)	2007-01-26	2013-07-24	科森生物科学公司	通过工程化生物合成制备的大环内酰胺
US8303960B2 (en) *	2007-02-27	2012-11-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Radiolabeled affibody molecules
US20100111943A1 (en) *	2007-03-22	2010-05-06	Medical College Of Georgia Research Institute, Inc	Compositions and methods for inhibiting cancer metastasis
JP2010523710A (ja) *	2007-04-12	2010-07-15	インフィニティ・ディスカバリー・インコーポレイテッド	ヒドロキノンアンサマイシン製剤
EP2190291B1 (de)	2007-08-23	2015-10-14	The Regents of The University of Colorado, A Body Corporate	Hsp90-hemmer mit modifizierter toxizität
CN101854955B (zh)	2007-09-10	2012-07-18	马萨诸塞大学	靶向线粒体的抗肿瘤剂
US20090186039A1 (en) *	2008-01-18	2009-07-23	Jang Sung-Key	Novel use of grp 94 in virus infection
US20090258869A1 (en) *	2008-02-08	2009-10-15	The Regents Of The University Of California	Methods and compounds for treatment or prevention of substance-related disorders
WO2010045442A1 (en)	2008-10-15	2010-04-22	Infinity Discovery, Inc.	Ansamycin hydroquinone compositions
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2011040421A1 (ja)	2009-09-29	2011-04-07	武田薬品工業株式会社	スクリーニング方法
CN102030764B (zh) *	2010-11-12	2012-07-04	中国医学科学院医药生物技术研究所	4，5双氢噻嗪酮格尔德霉素及其制备方法
WO2012082765A2 (en)	2010-12-16	2012-06-21	The United State Of America. As Represented By The Secretary Department Of Health And Human Services	Methods for decreasing body weight and treating diabetes
CN102603635B (zh) *	2011-01-21	2016-08-03	杭州华东医药集团生物工程研究所有限公司	格尔德霉素衍生物及其制备方法和用途
US8921533B2 (en)	2011-07-25	2014-12-30	Chromatin Technologies	Glycosylated valproic acid analogs and uses thereof
US9603829B2 (en)	2011-11-14	2017-03-28	The Regents Of The University Of Colorado, A Body Corporate	HSP90 inhibitors with modified toxicity
CN102552150B (zh) *	2012-03-02	2013-10-30	首都医科大学	一种格尔德霉素脂质体的制备及应用
WO2017027810A2 (en)	2015-08-12	2017-02-16	The General Hospital Corporation	Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2018160772A1 (en)	2017-02-28	2018-09-07	The United State Of America, As Represented By The Secretary, Department Of Health & Human Services	Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2020146758A1 (en)	2019-01-10	2020-07-16	The General Hospital Corporation	Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55111469A (en)	1979-02-19	1980-08-28	Kaken Pharmaceut Co Ltd	Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US4261989A (en) *	1979-02-19	1981-04-14	Kaken Chemical Co. Ltd.	Geldanamycin derivatives and antitumor drug
JPS55111470A (en)	1979-02-19	1980-08-28	Kaken Pharmaceut Co Ltd	Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JPS55111419A (en)	1979-02-20	1980-08-28	Kaken Pharmaceut Co Ltd	Antitumorigenic agent
WO1995001342A1 (en) *	1993-06-29	1995-01-12	Pfizer Inc.	Ansamycin derivatives as antioncogene and anticancer agents
WO1995007935A1 (en) *	1993-09-14	1995-03-23	Merck & Co., Inc.	cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE
US5932566A (en) *	1994-06-16	1999-08-03	Pfizer Inc.	Ansamycin derivatives as antioncogene and anticancer agents
WO1996034525A1 (en) *	1995-05-02	1996-11-07	The Regents Of The University Of California	Inducement of thermotolerance with benzoquinonoid ansamycins
US5958892A (en) *	1996-07-30	1999-09-28	Board Of Regents, The University Of Texas System	2-methoxyestradiol-induced apoptosis in cancer cells
US5948814A (en) *	1997-02-20	1999-09-07	The Curators Of The University Of Missouri	Genistein for the treatment of cystic fibrosis
US5952175A (en) *	1997-10-09	1999-09-14	Incyte Pharmaceuticals, Inc.	DNA encoding a human progesterone receptor complex p23-like protein
US5968921A (en) *	1997-10-24	1999-10-19	Orgegon Health Sciences University	Compositions and methods for promoting nerve regeneration

2002
- 2002-03-28 CA CA2430692A patent/CA2430692C/en not_active Expired - Lifetime
- 2002-03-28 US US10/432,581 patent/US6890917B2/en not_active Expired - Lifetime
- 2002-03-28 JP JP2002577794A patent/JP4213472B2/ja not_active Expired - Lifetime
- 2002-03-28 AU AU2002307020A patent/AU2002307020B2/en not_active Expired
- 2002-03-28 PT PT02757908T patent/PT1373215E/pt unknown
- 2002-03-28 WO PCT/US2002/010097 patent/WO2002079167A1/en not_active Ceased
- 2002-03-28 AT AT02757908T patent/ATE334119T1/de active
- 2002-03-28 KR KR1020037008551A patent/KR100831133B1/ko not_active Expired - Lifetime
- 2002-03-28 ES ES02757908T patent/ES2268068T3/es not_active Expired - Lifetime
- 2002-03-28 DE DE60213386T patent/DE60213386T2/de not_active Expired - Lifetime
- 2002-03-28 SI SI200220013A patent/SI21369A/sl not_active IP Right Cessation
- 2002-03-28 CN CNB028034651A patent/CN1262542C/zh not_active Expired - Lifetime
- 2002-03-28 MX MXPA03007856A patent/MXPA03007856A/es active IP Right Grant
- 2002-03-28 IL IL15612202A patent/IL156122A0/xx unknown
- 2002-03-28 EP EP02757908A patent/EP1373215B1/de not_active Expired - Lifetime
- 2002-03-28 NZ NZ526133A patent/NZ526133A/en not_active IP Right Cessation
- 2002-03-28 DK DK02757908T patent/DK1373215T3/da active
2003
- 2003-05-26 IL IL156122A patent/IL156122A/en unknown
- 2003-05-29 ZA ZA200304178A patent/ZA200304178B/en unknown
2006
- 2006-09-12 CY CY20061101299T patent/CY1107484T1/el unknown

Also Published As

Publication number	Publication date
MXPA03007856A (es)	2003-12-04
US6890917B2 (en)	2005-05-10
PT1373215E (pt)	2006-12-29
EP1373215A1 (de)	2004-01-02
SI21369A (sl)	2004-06-30
ES2268068T3 (es)	2007-03-16
CA2430692C (en)	2011-05-31
AU2002307020B2 (en)	2007-06-28
ZA200304178B (en)	2004-02-17
DK1373215T3 (da)	2006-11-13
CY1107484T1 (el)	2013-03-13
DE60213386T2 (de)	2006-11-23
CA2430692A1 (en)	2002-10-10
KR20040023581A (ko)	2004-03-18
CN1484639A (zh)	2004-03-24
EP1373215B1 (de)	2006-07-26
IL156122A0 (en)	2003-12-23
DE60213386D1 (de)	2006-09-07
JP2004519514A (ja)	2004-07-02
US20040053909A1 (en)	2004-03-18
CN1262542C (zh)	2006-07-05
NZ526133A (en)	2005-08-26
WO2002079167A1 (en)	2002-10-10
IL156122A (en)	2010-11-30
KR100831133B1 (ko)	2008-05-20
JP4213472B2 (ja)	2009-01-21

Legal Events

Date

Code

Title

Description

2007-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1373215

Country of ref document: EP

Publication	Publication Date	Title
DE60213386D1 (de)	2006-09-07	Geldanamycinderivate zur krebsbehandlung
AU2003253877A1 (en)	2004-02-02	Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
WO2005000213A8 (en)	2005-06-23	Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
AU2002236765A1 (en)	2002-07-30	Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
DE60222137D1 (de)	2007-10-11	Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
NO20014842D0 (no)	2001-10-04	Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
WO2002005791A3 (en)	2003-01-03	Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
NZ515567A (en)	2004-03-26	Method for treating chronic pain using MEK inhibitors
WO2004091540A3 (en)	2006-02-02	Methods of treating pain and compositions for use therefor
WO2005000212A3 (en)	2005-03-24	Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
NO20050450L (no)	2005-05-02	Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
EP1631267A4 (de)	2006-07-12	Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
ATE368455T1 (de)	2007-08-15	Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
GB0020504D0 (en)	2000-10-11	Therapeutic method
AU2003250190A1 (en)	2004-02-23	Combination of an aromatase inhibitor with a bisphosphonate
EP1262197A3 (de)	2002-12-18	Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
JO3446B1 (ar)	2020-07-05	طريقة لمعالجة الأرق الأولي
PL357179A1 (en)	2004-07-26	Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
PL367089A1 (en)	2005-02-21	Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
PL367707A1 (en)	2005-03-07	Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
WO2003079748A3 (en)	2003-11-27	Potentiation of cancer therapies by znf217 inhibition
MXPA01007031A (es)	2004-08-12	Metodo para tratar enfermedades acrdiacas cronicas.
IL153426A0 (en)	2003-07-06	Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
BR0308976A (pt)	2005-01-11	Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
WO2005102367A3 (en)	2006-10-19	Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer